During the past decade, The Medical Arts Health Research Group conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 26 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 16 clinical trials were completed. i.e. 145.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Medical Arts Health Research Group" #1 sponsor was "Pfizer" with 7 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Biogen" with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Medical Arts Health Research Group" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Pfizer" with 2 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "JSS Medical Research Inc." with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "The Medical Arts Health Research Group" are "Alzheimer's Disease" (11 trials), "Alzheimer Disease" (5 trials), "Cardiovascular Disease" (3 trials), "Crohn's Disease" (3 trials) and "Alopecia Areata" (2 trials). Many other conditions were trialed in "The Medical Arts Health Research Group" in a lesser frequency.

Most popular intervention types in "The Medical Arts Health Research Group" are "Drug" (49 trials), "Other" (5 trials), "Biological" (4 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (32 trials), "Guselkumab" (3 trials), "Aducanumab (BIIB037)" (2 trials), "BI 425809 dose 1" (2 trials) and "BI 425809 dose 2" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Medical Arts Health Research Group" are 50 trials for "All" genders.

Currently, there are NaN active trials in "The Medical Arts Health Research Group". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 28 completed trials in The Medical Arts Health Research Group, 1 suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in The Medical Arts Health Research Group, 1 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".